Factor V Leiden: How the Mutation Increases Blood Clot Risk

Factor V Leiden is the most common inherited clotting disorder, caused by a single mutation in the gene for clotting factor V that makes blood more prone to forming clots in veins. Roughly 3 to 8 percent of people of European descent carry at least one copy of the mutation, and in some populations the frequency reaches 15 percent. Despite its prevalence, most carriers never develop a clot. The mutation’s significance depends heavily on whether you carry one copy or two, what other risk factors are in play, and whether you are in a high-risk situation like pregnancy or hormonal contraceptive use.

What the Mutation Actually Does

Your blood has a built-in braking system for clotting. After a clot forms to stop bleeding, a protein called activated protein C (APC) comes along and chops up clotting factor Va at specific sites to shut down the process. Factor V Leiden is a single-letter change in the DNA (G to A at position 1691) that swaps one amino acid for another right at one of APC’s main cutting sites. The result: the mutant factor Va gets broken down about ten times more slowly than the normal version, so clots persist longer than they should.¹ This sluggish inactivation creates a subtle but real bias toward excessive clotting, especially in veins.

The mutation was identified in the early 1990s by Björn Dahlbäck’s laboratory, which had noticed that some patients’ blood plasma resisted the anticoagulant action of APC. The underlying genetic cause was traced to the factor V gene shortly after, and the mutation was named “Leiden” for the Dutch city where the gene variant was characterized.² It remains the single most common genetic risk factor for venous blood clots discovered to date.

One Copy Versus Two

Factor V Leiden is inherited in a straightforward way: you can carry one mutant copy (heterozygous) or two (homozygous). The difference in clot risk between the two is enormous. Heterozygous carriers face roughly a three- to sevenfold increase in the risk of a first venous clot compared with noncarriers.³ In a large Danish population study, the adjusted hazard ratio for heterozygous carriers was about 2.7 for venous thromboembolism overall.⁴

Homozygous carriers live in a different risk category altogether. Their clot risk is estimated at 50 to 80 times that of someone without the mutation.⁵ Homozygous individuals tend to have their first clot about a decade earlier than heterozygous carriers (average age 31 versus 44 in one study), and the absolute yearly risk climbs with age, reaching several percentage points per year in older homozygous individuals. The same study noted that most people homozygous for Factor V Leiden will experience at least one clot during their lifetime.

Still, even among heterozygous carriers, the absolute risk of a clot in any given year remains low. Most carriers go their entire lives without a venous thromboembolism. The mutation is better understood as a background risk amplifier: it does not cause clots on its own so much as it lowers the threshold at which other triggers can push the system over the edge.

Oral Contraceptives and the Multiplied Risk

If there is one practical message that matters most for Factor V Leiden carriers, it is the interaction with estrogen-containing oral contraceptives. Combined birth control pills independently raise clot risk in all women by a modest amount. Add the Leiden mutation and the risks do not simply add up; they multiply. A landmark study found that women who both used oral contraceptives and carried the mutation faced a clot risk more than 30-fold higher than women who had neither risk factor.⁶

The risk is especially steep in the first couple of years of contraceptive use. A large genetic study of women using oral contraceptives found that among those with Factor V Leiden, the hazard ratio during the first two years of use was about 5.7, dropping to about 2 in subsequent years.⁷ This does not mean carriers can never use hormonal contraception, but it does mean the decision warrants a careful conversation with a clinician about alternative methods, particularly progestin-only options, which carry far less clot risk.

In the homozygous women from the study on Factor V Leiden homozygosity, oral contraceptive use was the most common triggering factor for thrombosis, and the study population skewed heavily female for that reason.⁸ Whether to screen all women before prescribing the pill has been debated for decades. Early commentary favored screening, but in practice the low absolute risk among heterozygous carriers means screening every potential pill user would flag millions of women for a clot that most would never get.⁹

Pregnancy Complications

Pregnancy is itself a pro-clotting state: the body ramps up clotting factors to prepare for delivery. For Factor V Leiden carriers, that natural shift adds to an already tilted balance. One concern is venous thromboembolism during pregnancy or the postpartum period. Another is whether the mutation contributes to pregnancy loss.

A systematic review and meta-analysis of prospective cohort studies found that women with Factor V Leiden had about a 52 percent higher odds of pregnancy loss compared with women without the mutation. The absolute numbers, though, were not dramatic: 4.2 percent of carriers experienced pregnancy loss versus 3.2 percent of noncarriers.¹⁰ That same review found no significant link between Factor V Leiden and pre-eclampsia or low birth weight.

A separate study looking at Dutch women found miscarriage in about 29 percent of carriers versus 17 percent of noncarriers, with an adjusted odds ratio of roughly 2.1 for any fetal loss. Homozygous carriers appeared to have an even higher risk, particularly of stillbirth, though the numbers were too small to reach firm statistical conclusions.¹¹ These findings explain why Factor V Leiden testing is sometimes ordered as part of a workup for recurrent pregnancy loss, especially when no other cause is found.¹²

Venous Clots but Not Heart Attacks

A common question after learning about Factor V Leiden is whether it increases the risk of arterial events like heart attacks and strokes. The short answer, based on available evidence, is that it does not appear to do so in any meaningful way. Factor V Leiden is primarily a risk factor for venous thromboembolism: deep vein thrombosis and pulmonary embolism. The clotting pathways involved in arterial disease, where plaques rupture and platelets aggregate, operate differently from the slow-flow, fibrin-rich clotting in veins.

A case-control study in Venezuela found a roughly fourfold increase in deep vein thrombosis risk among carriers but no association at all with acute heart attack or stroke.¹³ This pattern holds broadly across the literature. If you carry the mutation and are worried about heart disease, the standard risk factors (cholesterol, blood pressure, smoking, diabetes, exercise) are far more relevant than your Factor V status.

When Two Mutations Meet

Factor V Leiden sometimes coexists with another inherited clotting mutation, prothrombin G20210A, which makes the body produce slightly too much of the clotting protein prothrombin. Carrying one copy of each, known as double heterozygosity, is not vanishingly rare and can push clot risk substantially higher. A study using data from FinnGen and the UK Biobank found that double heterozygous individuals had an odds ratio for venous thromboembolism of about 5.2 compared with people carrying neither mutation, a level of risk that approximated that of being homozygous for Factor V Leiden alone.¹⁴

Women with this double heterozygous genotype face a particularly sharp risk. In one study, female double heterozygotes developed their first clot on average nearly a decade earlier than noncarriers or single heterozygotes, with oral contraceptive use again the most common trigger.¹⁵ People with homozygous Factor V Leiden or compound heterozygosity are often considered for long-term anticoagulation after a first unprovoked clot, given the high rate of recurrence.¹⁶

Treatment After a Clot

When a Factor V Leiden carrier does develop a venous clot, treatment follows the same broad playbook as for anyone with a venous thromboembolism: anticoagulant medication to thin the blood and prevent clot growth or recurrence. For decades, warfarin (a vitamin K antagonist) was the standard long-term choice. Newer direct oral anticoagulants (DOACs) like rivaroxaban and apixaban have become widely used in the general population, and there has been a real question about whether they work as well in people with severe inherited thrombophilia.

The evidence so far suggests they do. An international subcommittee review found that DOACs and warfarin showed comparable rates of recurrent clots and bleeding in patients with severe inherited thrombophilia.¹⁷ A study specifically comparing DOACs with warfarin in patients homozygous for Factor V Leiden or carrying the prothrombin mutation found no significant difference in recurrent clot rates or major bleeding between the two groups.¹⁸ DOACs are easier to manage (no regular blood-test monitoring, fewer food interactions), which makes them an appealing option.

One caveat: a single-center retrospective study found that carriers of Factor V Leiden or the prothrombin mutation who were on DOACs had a higher cumulative incidence of recurrent clots (roughly 17 to 19 percent) than patients without those mutations (about 3 percent), even though bleeding rates were similar.¹⁹ This finding does not necessarily mean DOACs fail these patients; rather, it highlights that high-risk thrombophilia comes with elevated recurrence no matter the drug. The decision about duration of treatment, whether months or lifelong, matters more for these patients than the specific anticoagulant chosen.

Should You Get Tested?

Given how common the mutation is and how rarely it causes problems on its own, the question of genetic testing is surprisingly fraught. The U.S. Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group recommended against routine testing in two scenarios: adults who have already had an unexplained venous clot, and asymptomatic family members of known carriers. Their reasoning was straightforward: in someone who has already clotted, knowing about the mutation does not change the core treatment decision, because extended anticoagulation has similar benefits regardless of mutation status. And for asymptomatic relatives, the potential harms of preventive blood thinners outweigh the benefits for the vast majority.²⁰

Testing makes more clinical sense in specific circumstances: a young person with an unprovoked clot in an unusual location, a woman considering estrogen-containing contraception who has a strong family history of clots, or a patient with recurrent pregnancy loss. Even then, the test result by itself rarely demands a dramatic change in management. It provides a piece of the risk puzzle rather than a clear treatment directive.

When testing is ordered, clinicians can choose between a blood-based phenotypic test (which measures how well activated protein C suppresses clotting in a plasma sample) and a genetic test (which looks directly for the DNA mutation). A long-running comparison found that the phenotypic test has near-total agreement with the genetic test and costs substantially less, potentially reducing testing expenses by up to 80 percent.²¹ The genetic test is definitive and can distinguish heterozygous from homozygous status, which matters for counseling and risk stratification.

Living with the Diagnosis

For many people, learning they carry Factor V Leiden triggers anxiety that does not always match their actual risk. A survey of diagnosed individuals found that 88 percent were glad to know their genetic status, but 43 percent reported increased worry afterward.²² This tension makes sense: the word “mutation” sounds alarming, but the practical implications for a heterozygous carrier without additional risk factors are modest.

The practical advice for carriers focuses on situational awareness rather than medication. Stay mobile on long flights and car rides. Stay hydrated. Tell your surgeon or obstetrician about your status before procedures or pregnancy. Consider avoiding estrogen-containing hormones if alternatives exist. Watch for early symptoms of a deep vein thrombosis (persistent calf swelling, warmth, redness) so that treatment can start quickly if one develops. A case report of a young adult with homozygous Factor V Leiden who developed extensive clotting after prolonged air travel illustrates how immobility and the mutation can conspire in dramatic fashion.²³ For most heterozygous carriers, though, these precautions are about being sensible, not about living in fear.

Why Is It So Common?

A mutation that predisposes you to dangerous blood clots seems like it should have been weeded out by natural selection. The fact that Factor V Leiden persists at frequencies as high as 15 percent in some European populations has led researchers to suspect it once conferred a survival advantage. The leading hypothesis relates to childbirth: women who clot a bit more efficiently are less likely to hemorrhage during and after delivery. A review of the evidence concluded that Factor V Leiden carriers tend to have lower blood loss around delivery and better hemoglobin levels, giving them an edge in eras when postpartum hemorrhage was a major cause of maternal death.²⁴

There may be other benefits too. One study found that Factor V Leiden carriers had improved 30-day survival in acute respiratory distress syndrome, a condition where lung inflammation and clotting interact in complex ways.²⁵ A slightly pro-clotting tendency could also help with wound healing and resistance to certain infections, though these ideas remain speculative. The overall picture is one of a trade-off: the mutation was probably beneficial before modern medicine made its downsides (deep vein thrombosis, pulmonary embolism) survivable, and before oral contraceptives and sedentary lifestyles introduced new clotting triggers that it interacts badly with.

Other Factor V Variants

Factor V Leiden gets all the attention, but it is not the only variant in the factor V gene. Factor V Cambridge and Factor V Hong Kong both involve mutations at a different APC cleavage site (position 306 instead of 506). When recreated in the lab, both variants showed APC resistance that was intermediate between normal factor V and Factor V Leiden, meaning they impair APC’s braking action but to a lesser degree.²⁶ In population studies, these variants are rare to nonexistent: a study in Tunisian women found neither Factor V Cambridge nor Factor V Hong Kong in patients or controls.²⁷ A Mexican study similarly found Cambridge and Liverpool absent, though Hong Kong appeared at 2 percent and a variant called the HR2 haplotype was found in 28 percent of thrombophilic patients.²⁸ The HR2 haplotype can produce mild APC resistance on its own and may amplify risk when coinherited with Factor V Leiden, though its independent contribution to clotting risk is still debated.

Factor V Leiden in Children

Blood clots in children are rare, but when they do occur, inherited thrombophilia is worth investigating. Factor V Leiden has been identified as a contributing factor in pediatric clotting events, including neonatal strokes. A study of 85 children and neonates with blood clots found that about 14 percent were heterozygous for Factor V Leiden. Among neonates specifically who had arterial strokes in the brain, the rate was 27 percent.²⁹ A separate case report described a newborn who developed seizures within hours of delivery and was found to have a stroke affecting both brain hemispheres, with heterozygous Factor V Leiden as the only identified risk factor.³⁰

These cases are striking but uncommon. For most children who carry the mutation, it will remain silent throughout childhood and may never cause problems at all. Pediatric thrombosis usually involves a combination of the genetic predisposition with an acute trigger: a central venous catheter, surgery, infection, or the hormonal changes of puberty. Knowing a child carries the mutation can help pediatricians make more informed decisions during high-risk medical situations, even if preventive anticoagulation would not be warranted in healthy carriers.